{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:15:46Z","timestamp":1793967346013,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273692"],"award-info":[{"award-number":["82273692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92169207"],"award-info":[{"award-number":["92169207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The persistence of XBB-containing vaccine-induced immunity against evolving SARS-CoV-2 variants remains uncertain, particularly in older adults, who are at increased risk of severe outcomes and may experience more rapid immune decline. We previously reported neutralizing antibody (nAb) responses 21 days after a single booster dose of trivalent XBB.1.5 (Tri\u2011XBB.1.5), bivalent Omicron XBB (Bi\u2011Omi\u2011XBB), or tetravalent XBB.1 (Tetra\u2011XBB.1) vaccines in a cohort of 90 older adults aged &gt;65 years. In this six-month longitudinal follow-up analysis of the same cohort, we assessed nAb durability and SARS-CoV-2 infections to extend our earlier findings. Six months post-vaccination, the nAb titers decreased over time, with 2.5\u20124.6-fold reductions in the geometric mean titer against the variants KP.3.1.1 and XEC; however, the nAb titer remained detectable in most participants. The Tri\u2011XBB.1.5 vaccine exhibited marginally better antibody persistence than the Bi\u2011Omi\u2011XBB and Tetra\u2011XBB.1 vaccines did, suggesting potential formulation-dependent differences in long-term immunogenicity. Twenty-seven participants experienced SARS-CoV-2 infection, including 11 (12.2%) confirmed by rapid antigen testing and 16 (17.8%) classified as probably based on serological evidence, with relatively frequent infections in bivalent and tetravalent recipients. Lower nAb titers on day 21 were linked to early infections, whereas late infections reflected antibody waning. Infections transiently increased nAb levels, but the elevated titers were not sustained. These findings highlight the importance of updating booster formulations and improving vaccine designs to address emerging immune-evasive variants.<\/jats:p>","DOI":"10.1038\/s41392-025-02437-y","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:03:04Z","timestamp":1759964584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neutralizing antibody durability and SARS-CoV-2 infection in older adults six months after XBB-containing vaccine booster"],"prefix":"10.1038","volume":"10","author":[{"given":"Rui-Rui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Ping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5194-5031","authenticated-orcid":false,"given":"Xue-Dong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-936X","authenticated-orcid":false,"given":"Xue-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2699-0652","authenticated-orcid":false,"given":"Guo-Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Man","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-304X","authenticated-orcid":false,"given":"Hai-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3916-1306","authenticated-orcid":false,"given":"Bing-Dong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-462X","authenticated-orcid":false,"given":"Mai-Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2437_CR1","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19\u201411 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---20-march-2020 (2020)."},{"key":"2437_CR2","doi-asserted-by":"crossref","unstructured":"Lenharo, M. WHO declares end to COVID-19\u2019s emergency phase. Nature. https:\/\/www.nature.com\/articles\/d41586-023-01559-z (2023).","DOI":"10.1038\/d41586-023-01559-z"},{"key":"2437_CR3","unstructured":"World Health Organization. COVID-19 weekly epidemiological update, special edition 174, 24 December 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/emergencies\/20241224_covid-19_epi_update_special-edition.pdf?sfvrsn=b0a6ddaf_1&download=true (2024)."},{"key":"2437_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"2437_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(23)00140-6","volume":"11","author":"LM Zaeck","year":"2023","unstructured":"Zaeck, L. M., GeurtsvanKessel, C. H. & de Vries, R. D. COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint. Lancet Respir. Med. 11, 395\u2013396 (2023).","journal-title":"Lancet Respir. Med."},{"key":"2437_CR6","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1016\/j.cell.2021.09.010","volume":"184","author":"M Cevik","year":"2021","unstructured":"Cevik, M., Grubaugh, N. D., Iwasaki, A. & Openshaw, P. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 184, 5077\u20135081 (2021).","journal-title":"Cell"},{"key":"2437_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1056\/NEJMc2103022","volume":"384","author":"GL Wang","year":"2021","unstructured":"Wang, G. L. et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N. Engl. J. Med. 384, 2354\u20132356 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR10","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMc2402779","volume":"390","author":"DY Lin","year":"2024","unstructured":"Lin, D. Y. et al. Durability of XBB.1.5 vaccines against Omicron subvariants. N. Engl. J. Med. 390, 2124\u20132127 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00540-7","volume":"7","author":"B Akache","year":"2022","unstructured":"Akache, B. et al. Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern. NPJ Vaccines 7, 118 (2022).","journal-title":"NPJ Vaccines"},{"key":"2437_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33549-6","volume":"13","author":"S Sridhar","year":"2022","unstructured":"Sridhar, S. et al. The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022. Nat. Commun. 13, 5794 (2022).","journal-title":"Nat. Commun."},{"key":"2437_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJMc2206711","volume":"387","author":"O Launay","year":"2022","unstructured":"Launay, O. et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N. Engl. J. Med. 387, 374\u2013376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83930-6","volume":"11","author":"G Sir Karakus","year":"2021","unstructured":"Sir Karakus, G. et al. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates. Sci. Rep. 11, 5804 (2021).","journal-title":"Sci. Rep."},{"key":"2437_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95086-4","volume":"11","author":"RD Turan","year":"2021","unstructured":"Turan, R. D. et al. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice. Sci. Rep. 11, 15799 (2021).","journal-title":"Sci. Rep."},{"key":"2437_CR17","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1002\/jmv.27881","volume":"94","author":"N Khorattanakulchai","year":"2022","unstructured":"Khorattanakulchai, N. et al. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern. J. Med. Virol. 94, 4265\u20134276 (2022).","journal-title":"J. Med. Virol."},{"key":"2437_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45180-8","volume":"15","author":"LM Coria","year":"2024","unstructured":"Coria, L. M. et al. A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection. Nat. Commun. 15, 997 (2024).","journal-title":"Nat. Commun."},{"key":"2437_CR19","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265\u20132278.e2214 (2022).","journal-title":"Cell"},{"key":"2437_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179 (2022).","journal-title":"Nat. Microbiol."},{"key":"2437_CR21","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1016\/S2665-9913(22)00216-8","volume":"4","author":"M Risk","year":"2022","unstructured":"Risk, M. et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol. 4, e775\u2013e784 (2022).","journal-title":"Lancet Rheumatol."},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.7326\/M22-1856","volume":"175","author":"GN Ioannou","year":"2022","unstructured":"Ioannou, G. N. et al. Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the Omicron (B.1.1.529) variant era. Ann. Intern. Med. 175, 1693\u20131706 (2022).","journal-title":"Ann. Intern. Med."},{"key":"2437_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01151-6","volume":"14","author":"XJ Wang","year":"2022","unstructured":"Wang, X. J. et al. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Genome Med. 14, 146 (2022).","journal-title":"Genome Med."},{"key":"2437_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112075","volume":"42","author":"KL Zhu","year":"2023","unstructured":"Zhu, K. L. et al. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. Cell Rep. 42, 112075 (2023).","journal-title":"Cell Rep."},{"key":"2437_CR26","doi-asserted-by":"crossref","unstructured":"Jacobsen, H. et al. Post-vaccination neutralization responses to Omicron sub-variants. Vaccines 10, 1757 (2022).","DOI":"10.3390\/vaccines10101757"},{"key":"2437_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114387","volume":"43","author":"XL Jiang","year":"2024","unstructured":"Jiang, X. L. et al. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection. Cell Rep. 43, 114387 (2024).","journal-title":"Cell Rep."},{"key":"2437_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114520","volume":"43","author":"P Li","year":"2024","unstructured":"Li, P. et al. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. Cell Rep. 43, 114520 (2024).","journal-title":"Cell Rep."},{"key":"2437_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01016-6","volume":"9","author":"K Xu","year":"2024","unstructured":"Xu, K. et al. Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera. NPJ Vaccines 9, 215 (2024).","journal-title":"NPJ Vaccines"},{"key":"2437_CR30","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations. Lancet Infect. Dis. 25, e6\u2013e7 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"2437_CR31","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect. Dis. 24, e482\u2013e483 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2437_CR32","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1016\/S1473-3099(24)00298-6","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect. Dis. 24, e416 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2437_CR33","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S1473-3099(24)00505-X","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y., Uriu, K., Okumura, K., Ito, J. & Sato, K. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant. Lancet Infect. Dis. 24, e609 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2437_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 2254 (2024).","journal-title":"Nat. Commun."},{"key":"2437_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","volume":"32","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315\u2013321.e313 (2024).","journal-title":"Cell Host Microbe"},{"key":"2437_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2023.11.012","volume":"32","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster. Cell Host Microbe 32, 25\u201334.e25 (2024).","journal-title":"Cell Host Microbe"},{"key":"2437_CR37","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 24, e82 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2437_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00751-24","volume":"15","author":"P Li","year":"2024","unstructured":"Li, P. et al. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. mBio 15, e0075124 (2024).","journal-title":"mBio"},{"key":"2437_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101701","volume":"5","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Rep. Med. 5, 101701 (2024).","journal-title":"Cell Rep. Med."},{"key":"2437_CR40","doi-asserted-by":"publisher","unstructured":"Ma, K. C. et al. Effectiveness of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineage hospitalization and a comparison of clinical severity\u2014IVY network, 26 hospitals, October 18, 2023-March 9, 2024. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciae405 (2024).","DOI":"10.1093\/cid\/ciae405"},{"key":"2437_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"R Link-Gelles","year":"2024","unstructured":"Link-Gelles, R. et al. Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. MMWR Morb. Mortal. Wkly Rep. 73, 77\u201383 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2437_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53842-w","volume":"15","author":"AR Caffrey","year":"2024","unstructured":"Caffrey, A. R. et al. Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System. Nat. Commun. 15, 9490 (2024).","journal-title":"Nat. Commun."},{"key":"2437_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-025-02132-y","volume":"10","author":"GJ Yang","year":"2025","unstructured":"Yang, G. J. et al. Neutralizing antibody responses to three XBB protein vaccines in older adults. Signal Transduct. Target Ther. 10, 48 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2437_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422 (2021).","journal-title":"Nature"},{"key":"2437_CR45","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/infdis\/jiab592","volume":"225","author":"MA Brockman","year":"2022","unstructured":"Brockman, M. A. et al. Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. J. Infect. Dis. 225, 1129\u20131140 (2022).","journal-title":"J. Infect. Dis."},{"key":"2437_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/10408363.2022.2038539","volume":"59","author":"KI Notarte","year":"2022","unstructured":"Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab Sci. 59, 373\u2013390 (2022).","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"2437_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR48","unstructured":"World Health Organization. Statement on the antigen composition of COVID-19 vaccines. https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines (2024)."},{"key":"2437_CR49","unstructured":"China Center for Disease Control and Prevention. The National Situation of COVID-19 Infections-October 2024. https:\/\/www.chinacdc.cn\/jksj\/xgbdyq\/202411\/t20241111_302498.html (2024)."},{"key":"2437_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55087-z","volume":"15","author":"J Yang","year":"2024","unstructured":"Yang, J. et al. Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials. Nat. Commun. 15, 10778 (2024).","journal-title":"Nat. Commun."},{"key":"2437_CR51","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMc2115596","volume":"385","author":"AY Collier","year":"2021","unstructured":"Collier, A. Y. et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N. Engl. J. Med. 385, 2010\u20132012 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2437_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","volume":"22","author":"BJ Laidlaw","year":"2022","unstructured":"Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7\u201318 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2437_CR53","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41586-023-06025-4","volume":"617","author":"WB Alsoussi","year":"2023","unstructured":"Alsoussi, W. B. et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature 617, 592\u2013598 (2023).","journal-title":"Nature"},{"key":"2437_CR54","volume":"44","author":"XD Song","year":"2024","unstructured":"Song, X. D. et al. Seroprevalence of SARS-CoV-2 neutralising antibodies and cross-reactivity to JN.1 one year after the BA.5\/BF.7 wave in China. Lancet Reg. Health West Pac. 44, 101040 (2024).","journal-title":"Lancet Reg. Health West Pac."},{"key":"2437_CR55","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."},{"key":"2437_CR56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.1097211","volume":"305","author":"DJ Smith","year":"2004","unstructured":"Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371\u2013376 (2004).","journal-title":"Science"},{"key":"2437_CR57","doi-asserted-by":"crossref","unstructured":"Noble, C. C. A. et al. Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response. J. Infect. 90, 106436 (2025).","DOI":"10.1016\/j.jinf.2025.106436"},{"key":"2437_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.105052","volume":"146","author":"H Scheiblauer","year":"2022","unstructured":"Scheiblauer, H. et al. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. J. Clin. Virol. 146, 105052 (2022).","journal-title":"J. Clin. Virol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02437-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:03:10Z","timestamp":1759964590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02437-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02437-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"336"}}